Please use this identifier to cite or link to this item: http://hdl.handle.net/11434/712
Title: Is there a place for cytoreduction in metastatic prostate cancer?
Epworth Authors: Costello, Anthony
Other Authors: Reeves, Fairleigh
Keywords: Prostate Cancer
Metastatic Prostate Cancer
mPCa
Radical Prostatectomy
RP
Radiotherapy
Multimodal Therapy
Treatment OutcomesTreatment Outcomes
Cytoreductive Treatment
Australian Prostate Cancer Research Centre Epworth HealthCare, Victoria, Australia
UroRenal, Vascular Clinical Institute, Epworth HealthCare, Victoria, Australia
Issue Date: Jul-2016
Publisher: Wiley
Citation: BJU Int. 2016 Jul;118(1):14-5.
Abstract: Cytoreductive treatment in metastatic prostate cancer (mPCa) primarily refers to local control of the primary tumour by radical prostatectomy (RP) or radiotherapy; however, extirpative treatment of limited metastatic disease by stereotactic body radiotherapy or surgical resection may further reduce or even possibly eliminate disease burden. This comment piece explores the theory and evidence for RP in the setting of mPCa.Cytoreductive treatment may now be an option when considered in the context of multimodal therapy. Large, multicentre randomized controlled trials are needed to establish its safety and efficacy. Until further evidence is available, cytoreductive RP should be undertaken in a clinical trial setting only.
URI: http://hdl.handle.net/11434/712
DOI: 10.1111/bju.13323
PubMed URL: http://www.ncbi.nlm.nih.gov/pubmed/26384467
ISSN: 1464-4096
1464-410X
Journal Title: BJU International
Type: Journal Article
Affiliated Organisations: Department of Urology and Surgery, University of Melbourne, Royal Melbourne Hospital, Parkville, Vic., Australia
Type of Clinical Study or Trial: Review
Appears in Collections:Cancer Services
UroRenal, Vascular
Epworth Prostate Centre

Files in This Item:
There are no files associated with this item.


Items in EKB are protected by copyright, with all rights reserved, unless otherwise indicated.